These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 29150194)

  • 21. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Кulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B
    J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season.
    Puig-Barberà J; Guglieri-López B; Tortajada-Girbés M; López-Labrador FX; Carballido-Fernández M; Mollar-Maseres J; Schwarz-Chavarri G; Baselga-Moreno V; Mira-Iglesias A; Díez-Domingo J;
    Vaccine; 2017 Dec; 35(52):7331-7338. PubMed ID: 29128380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Partial Protection Induced by 2011-2012 Influenza Vaccine Against Serologically Evidenced A(H3N2) Influenza Virus Infections in Elderly Institutionalized People.
    Camilloni B; Basileo M; Menculini G; Tozzi P; Iorio AM
    Adv Exp Med Biol; 2016; 897():45-53. PubMed ID: 26577530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of effect of a booster dose of influenza vaccine in hemodialysis patients.
    Tanzi E; Amendola A; Pariani E; Zappa A; Colzani D; Logias F; Perego A; Zanetti AR
    J Med Virol; 2007 Aug; 79(8):1176-9. PubMed ID: 17596830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
    J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune response to influenza vaccination in community-dwelling Chinese elderly persons.
    Hui SL; Chu LW; Peiris JS; Chan KH; Chu D; Tsui W
    Vaccine; 2006 Jun; 24(25):5371-80. PubMed ID: 16713661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years.
    Nabeshima S; Kashiwagi K; Murata M; Kanamoto Y; Furusyo N; Hayashi J
    J Med Virol; 2007 Mar; 79(3):320-5. PubMed ID: 17245715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.
    Hiroi S; Morikawa S; Nakata K; Maeda A; Kanno T; Irie S; Ohfuji S; Hirota Y; Kase T
    Hum Vaccin Immunother; 2015; 11(2):386-90. PubMed ID: 25692378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influenza vaccination given at least 2 weeks before delivery to pregnant women facilitates transmission of seroprotective influenza-specific antibodies to the newborn.
    Blanchard-Rohner G; Meier S; Bel M; Combescure C; Othenin-Girard V; Swali RA; Martinez de Tejada B; Siegrist CA
    Pediatr Infect Dis J; 2013 Dec; 32(12):1374-80. PubMed ID: 24569309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody response to whole-virus and split-virus influenza vaccines in successful ageing.
    McElhaney JE; Meneilly GS; Lechelt KE; Beattie BL; Bleackley RC
    Vaccine; 1993; 11(10):1055-60. PubMed ID: 8212827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine.
    Seo YB; Lee J; Song JY; Choi HJ; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2016; 12(2):478-84. PubMed ID: 26431466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.
    Loebermann M; Anders G; Brestrich G; Fritzsche C; Klammt S; Boršo D; Frimmel S; Riebold D; Reisinger EC
    Vaccine; 2011 Feb; 29(6):1228-34. PubMed ID: 21167116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody responses to trivalent influenza vaccine in Iranian adults infected with human immunodeficiency virus.
    Rasoolinejad M; Jafari S; Montazeri M; Mohseni M; Foroughi M; Moradmand Badie B; Saatian M; Marashi SM; Mokhtari Azad T
    Acta Med Iran; 2013 Apr; 51(3):148-52. PubMed ID: 23605597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine.
    Zeman AM; Holmes TH; Stamatis S; Tu W; He XS; Bouvier N; Kemble G; Greenberg HB; Lewis DB; Arvin AM; Dekker CL
    Pediatr Infect Dis J; 2007 Feb; 26(2):107-15. PubMed ID: 17259871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine.
    Sullivan SJ; Jacobson R; Poland GA
    Expert Rev Vaccines; 2010 Oct; 9(10):1127-33. PubMed ID: 20923264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Stukova M; Buzitskaya Z; Кulmagambetov I; Davlyatshin T; Khairullin B
    Hum Vaccin Immunother; 2018 Mar; 14(3):609-614. PubMed ID: 29112488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of the trivalent influenza vaccination in Thai patients with hemodialysis or kidney transplant compared with healthy volunteers.
    Krairittichai U; Chittaganpitch M
    J Med Assoc Thai; 2013 Mar; 96 Suppl 3():S1-7. PubMed ID: 23682516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
    Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.